Partners aim to develop new instruments

The Brien Holden Vision Institute has taken a controlling share in US-based diagnostic technology development company Quantum Catch that makes high resolution systems for detection and diagnosis of eye diseases and other health conditions.

Quantum Catch is a social enterprise, founded in 2009, focusing on the design, manufacture and sale of affordable, high quality medical devices to make the detection and screening of disease, as well as measurement of the progression of chronic disease, easy and convenient.

Professor Brien Holden, CEO of the Brien Holden Vision Institute and Vision CRC, and now chair of the board of Quantum Catch, said that all the company's principals were dedicated to advances in eye health, with a strong, committed social agenda. The Institute, he said, would combine its clinical, epidemiology, eye care technology and delivery knowledge with that of Quantum Catch to take the next step in developing instruments that could capture, analyse and diagnose conditions such as glaucoma, retinal disease, early signs of vascular and other chronic diseases and refractive error.